Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Young Boys seals 6th Swiss soccer league title in 7 years after rallying from firing coach Wicky
GENEVA (AP) — Young Boys sealed its sixth Swiss league title in seven years by winning at Servette 12024-05-21- Xuzhou is a major city in east China's Jiangsu province with a time-honored history and splendid cul2024-05-21
Qingdao top Shandong to seal playoffs spot in CBA
The Qingdao Eagles cruised past the Shandong Heroes 119-102 to secure a place in the playoffs, while2024-05-21Kimmich heads Bayern past Arsenal, into UCL semis
Joshua Kimmich's sole goal helped Bayern Munich progress into the UEFA Champions League last fou2024-05-21Four people killed in a house explosion in southwestern Missouri
GOODHOPE, Mo. (AP) — Four people in rural Missouri died when an explosion that could be heard 10 mil2024-05-21Giant pandas set to travel from China to San Diego Zoo
SAN DIEGO (AP) — A pair of giant pandas will soon make the journey from China to the U.S., where the2024-05-21
atest comment